FDA Outlines Strategy To Review Infant Formula Production Rules

FDA Outlines Strategy To Review Infant Formula Production Rules
  • The FDA would review guidance and rules about manufacturing infant formula as part of its strategy to prevent bacterial illness similar to Abbott Laboratories ABT products this year.
  • The FDA will also consider establishing a dedicated group of investigators and realigning staff across two of its divisions to better support regulatory oversight of infant formula, among other measures.
  • The agency also seeks to improve oversight of the safe production of powdered infant formula.
  • Related: Infant Formula Fiasco Weighs On Abbott's Q3 Earnings, Still, It Raised FY22 EPS Guidance.
  • The FDA's statement follows a major shortage of baby formula earlier this year due to a shutdown at Abbott's plant in Michigan after complaints of infection by a bacteria called cronobacter sakazakii.
  • Between September 2021 and February 2022, the FDA received complaints about four cases of illness or death in infants who consumed powdered infant formula. 
  • FDA's internal review concluded that numerous shortcomings hampered the agency's response to the U.S. infant formula supply problems this year.
  • Price Action: ABT shares are up 0.93% at $104.10 on the last check Wednesday.
  • Photo by Pexels from Pixabay

Posted In: BriefsLarge CapNewsHealth CareFDAGeneral